FDAnews
www.fdanews.com/articles/124178-fda-accepts-javelin-8217-s-submission-files-new-drug-application-for-dyloject

FDA Accepts Javelin’s Submission, Files New Drug Application for Dyloject

February 2, 2010
Myriad Pharmaceuticals Inc. Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted Javelin Pharmaceuticals’ submission and filed a New Drug Application for Dyloject, an investigational, injectable NSAID for the management of acute moderate-to-severe postoperative pain in adults.
CNNMoney